$0.41-10.9%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 9, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.9M | $276K | +572.46% |
| Free Cash Flow | -$2M | -$2.2M | +11.15% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Scinai Immunotherapeutics Ltd. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing innovative therapies for inflammation and immunology. Its wholly owned subsidiary, Scinai Biopharma Services Ltd., operates a contract development and manufacturing organization (CDMO), serving biotechnology and pharmaceutical customers through facilities in Jerusalem and Yavne, Israel. The Company develops its NanoAb platform through research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen in Germany.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Scinai Immunotherapeutics Ltd. filed on November 9, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.